rethinkPeptides Search
Menu
Study breakdown

Recombinant Collagen Peptides Show Promise as Bioactive Dermal Fillers for Skin Rejuvenation

evidence
The takeaway

Recombinant human collagen III peptides stimulated skin cell matrix production, improved epidermis regeneration, and enhanced dermal remodeling in both 2D cell cultures and a novel 3D biomimetic skin model.

7 matrix genes upregulated

Collagen I, III, Elastin, Fibrillin 1, and Hyaluronic acid synthases 1-3 were all significantly upregulated by recombinant collagen III peptide treatment

What the researchers found

Recombinant human collagen III (rhCol III) peptides significantly upregulated matrix remodeling genes in human fibroblasts, including Collagen types I and III, Elastin, Fibrillin 1, and Hyaluronic acid synthases 1, 2, and 3. In a novel 3D filler biomimetic skin model, the peptides directly bound to the dermal scaffold and demonstrated beneficial effects on both skin layers: improved epidermal regeneration (shown by Ki67 and COL17A1 markers) and enhanced dermal remodeling (FBN1 and glycosaminoglycans).

Transcriptomic analysis revealed the peptides downregulated inflammation, senescence, and apoptosis pathways while upregulating integrin binding and extracellular matrix formation — suggesting mechanisms for skin rejuvenation beyond simple volume filling.

Why it matters

Most dermal fillers work by adding volume, but collagen peptide-based fillers could actively stimulate the skin's own repair and rejuvenation processes. This research provides mechanistic evidence that recombinant collagen peptides don't just fill — they actually improve skin biology by boosting collagen production, reducing inflammation, and combating cellular aging.

How the study worked

The study used 2D human fibroblast cultures to assess mRNA-level gene expression changes, then developed a novel 3D in vitro filler biomimetic skin model to evaluate tissue-level effects. Tissue morphology, epidermal proliferation and differentiation, and dermal extracellular matrix deposition were assessed. Transcriptomic analysis was performed to identify molecular pathways underlying the observed changes.

What this study cannot tell us

This was entirely an in vitro study using cell cultures and a 3D skin model. The authors acknowledge a significant gap between their biomimetic model and actual injection in living skin. No human clinical data was presented. The 3D model, while novel, may not capture the full complexity of in vivo skin aging, immune responses, or filler degradation over time.

How to read the evidence

This is an in vitro study using 2D cell cultures and a 3D biomimetic skin model. While the multi-level approach (gene expression, tissue morphology, transcriptomics) provides thorough mechanistic evidence, the lack of in vivo or clinical data limits the ability to draw conclusions about real-world efficacy.

When this study was published

Published in 2025, this is very recent research at the frontier of bioactive peptide-based aesthetics and dermal filler development.

The bigger picture

This study reflects the growing trend of bioactive peptide-based aesthetics — moving beyond inert fillers toward products that actively promote tissue regeneration. Recombinant collagen peptides represent an intersection of biotechnology and dermatology, offering potentially superior outcomes compared to traditional hyaluronic acid fillers by stimulating the skin's natural repair mechanisms.

Questions still open

  • Will the matrix-stimulating effects of rhCol III peptides persist after injection into human skin, where immune and degradation processes are active?
  • How do recombinant collagen peptide fillers compare to hyaluronic acid fillers in clinical outcomes for skin rejuvenation?
  • Could these collagen peptides be combined with other bioactive compounds to enhance their regenerative effects?

Common questions

What are recombinant collagen peptides and how are they different from regular fillers?
Recombinant collagen peptides are lab-produced fragments of human collagen protein. Unlike traditional fillers (like hyaluronic acid) that primarily add volume, these peptides appear to actively stimulate skin cells to produce their own collagen, elastin, and hyaluronic acid, potentially offering rejuvenation benefits beyond simple filling.
Is this treatment available to patients now?
Not yet as validated clinical products. This study demonstrates the biological potential of recombinant collagen peptides in laboratory models, but the authors note that clinical trials in humans are still needed to confirm whether these benefits translate to real-world injection results.

Read the original research

In Vitro Bioactivity of a Recombinant Human Collagen Peptide in a Filler Biomimetic Skin Model.

Journal of cosmetic dermatology, 24(12), e70592

Citation

He, Chunyan; Wang, Ranran; Zhang, Qiao; Wang, Yehong; Huang, Nan. (2025). In Vitro Bioactivity of a Recombinant Human Collagen Peptide in a Filler Biomimetic Skin Model.. Journal of cosmetic dermatology, 24(12), e70592. https://doi.org/10.1111/jocd.70592